中國航天萬源(01185.HK)總裁及董事長等職位變動
中國航天萬源(01185.HK)公佈,劉中兵已獲委任爲執行董事、總裁、提名委員會成員及發展及投資委員會成員,自今日(13日)起生效。劉中兵已與公司訂立委任書,任期僅至其獲委任後首次股東大會止,並將合資格於該次大會上重選連任,其後須根據公司組織章程大綱及細則,至少每三年一次於各次股東周年大會上輪值退任。
董事會宣佈,韓慶平因其退休計劃,已遞交辭任執行董事、董事長、提名委員會主席、發展及投資委員會主席、薪酬委員會成員及上市規則授權代表,即日起生效。同日起,李磊已獲委任爲董事長及上市規則授權代表,並不再擔任總裁。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.